NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitve Revision Award (R01)

Post Date

February 26th 2010

Application Due Date

August 4th 2010

Funding Opportunity Number

RFA-AR-11-004

CFDA Number(s)

93.846

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $1000000

• Award Range:

  $None - $650000

Grant Description

Purpose. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) solicits Accelerating Research Translation (ART) applications in musculoskeletal and skin tissue engineering and regenerative medicine (TE/RM). The ART awards intend to offer revision support (formerly referred to as a competing supplement) to active NIAMS R01, P01 and P50 (parent) grants for conducting large animal pre-clinical studies with the potential to immediately lead to human trials in musculoskeletal and skin TE/RM. These studies will 1) provide data required for Phase I/II human clinical trials in musculoskeletal and skin TE/RM, 2) demonstrate efficacy of a TE/RM therapy in musculoskeletal and skin TE/RM, or 3) develop pre-clinical large animal models that will have the potential to immediately lead TE/RM research into Phase I/II clinical trials. Early stage translational studies using small animals such as rodent and rabbit are not responsive to this FOA. Mechanism of Support. This FOA will utilize the NIH revision to R01 grant mechanism and runs in parallel with a FOA (RFA-AR-11-005) of identical scientific scope that solicits applications under the NIAMS P01 and P50 mechanisms. Funds Available and Anticipated Number of Awards. The NIAMS plans to commit $1M in total cost in FY 2011 to make 1 to 3 ART awards for both RFA-AR-11-004 and RFA-AR-11-005. Awards issued under this FOA are contingent upon the availability of funds and the submission of meritorious applications.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-11-004.html